# Dario

> DarioHealth combines connected health devices, mobile software, personalized coaching and provider-backed care to support diabetes, hypertension, weight management, musculoskeletal and behavioral health. It sells subscriptions to employers and health plans and devices and programs directly to consumers, drawing on its origins in smartphone-connected glucose monitoring.

- **Founded:** 2011
- **Headquarters:** New York, United States
- **Founders:** Oren Fuerst (Co-founder; founding chairman and CEO), David Weintraub (Co-founder and founding director), Shilo Ben Zeev (Co-founder; founding COO and later president)
- **Products:** Dario smart glucose meter and app, Hypertension management, Prediabetes and weight management, Dario Move, Dario Mind
- **Notable:** FDA clearance for blood glucose monitoring system in 2015., Acquired Upright and wayForward in 2021, Physimax in 2022 and Twill in 2024., Reported 70 published clinical research studies on its 2024 company timeline.

## Products & services

- **Dario smart glucose meter and app** — Pocket-sized finger-stick blood glucose system connected to compatible smartphones; the app automatically records readings and supports tracking and sharing. US diabetes solution launched in 2016 following 2015 FDA clearance.
- **Hypertension management** — Connected blood pressure monitor, mobile tracking, progress reports, education and coaching.
- **Prediabetes and weight management** — Connected scale, habit support, nutrition and activity coaching within its cardiometabolic offering.
- **Dario Move** — Musculoskeletal program with tailored exercise plans, coaching and sensor-based movement and posture feedback. Company timeline dates MSK launch to 2020.
- **Dario Mind** — Behavioral health support combining self-guided programs, digital coaching, peer groups and expert content. Company timeline dates behavioral-health launch to 2021.
- **Dario Connect** — Digital communities, educational content and navigation to Dario and other services; capabilities broadened through Twill.
- **Integrated GLP-1 Program** — Announced July 2026 with Beluga Health to combine monitoring and coaching with licensed-provider evaluation, prescribing when appropriate and clinical oversight; commercial availability was expected in fall 2026.

## Achievements

- FDA clearance for blood glucose monitoring system in 2015.
- Acquired Upright and wayForward in 2021, Physimax in 2022 and Twill in 2024.
- Reported 70 published clinical research studies on its 2024 company timeline.
- October 2026 Aon evidence review supported estimated annual population-level healthcare-cost reductions of 2.5%-7.2%, subject to substantial methodological and population limitations.

## Latest updates

- **2026-10** — Announced Aon review of 17 Dario-identified studies supporting estimated 2.5%-7.2% annual healthcare-cost savings; Aon did not verify underlying data or audit the studies.
- **2026-09** — Announced unnamed New Jersey health-plan contract through Amwell, representing about 1.5 million covered lives; launch and revenue expected Q1 2027.
- **2026-08** — Reported Q2 revenue of $5.177 million and net loss of $7.9 million; also announced women’s health and sleep program extensions.
- **2026-07** — Announced Integrated GLP-1 Program with Beluga Health and a $23.5 million gross registered direct financing.

## Links

- Website: https://www.dariohealth.com/
- LinkedIn: https://www.linkedin.com/company/dariohealth/
- Twitter/X: https://twitter.com/DarioHealth
- YouTube: https://www.youtube.com/user/myDario2013
- Instagram: https://instagram.com/dariohealth
- Facebook: https://www.facebook.com/DarioHealth

---

Profile page: https://yespress.io/dario
Published by YesPress — https://yespress.io
Last updated: 2026-10-23